natgillin/translations-raw huggingface dataset:
Amounts to be administered and administration route Dosage
Količine koje se primjenjuju i način primjene Doziranje
Amounts to be administered and administration route In feed use for pigs:
Količine koje se primjenjuju i put primjene Primjena u hrani za svinje:
Amounts to be administered and administration route Inspired Concentration:
Količine koje se primjenjuju i put primjene Udahnuta koncentracija:
Amounts to be administered:
Količina za primjenu:
AmpC types) are present in conjunction with reduced permeability, arising by the loss of one or more outer membrane porins, or with up-regulated efflux.
AmpC tipa) prisutna i ograničena propusnost za lijek uslijed gubitka jednog ili više porina na vanjskoj membrani ili povećan efluks.
amphetamine or amphetamine derivatives;
amfetamin ili derivate amfetamina;
Amphetamine Ritonavir dosed as an antiretroviral agent is likely to inhibit CYP2D6 and as a result is expected to increase concentrations of amphetamine and its derivatives.
Amfetamin Ritonavir primijenjen kao antiretrovirusni lijek vjerojatno će inhibirati CYP2D6 te se zbog toga može očekivati povećanje koncentracija amfetamina i njegovih derivata.
amphetamines
amfetamine
Amphiphilic agents
Amfifilična sredstva
amphiphilic medicines used to treat heart arrhythmias (such as amiodarone), or statins used to treat high cholesterol
amfifilne lijekove koji se primjenjuju za liječenje srčanih aritmija (kao što je amiodaron) ili statine koji se primjenjuju za liječenje povišenog kolesterola
Amphotericin B
Amfotericin B
Amphotericin B, cefalotin, polymyxins (used to treat microbial infections), ciclosporin, tacrolimus (used to reduce the activity of immune system).
Amfotericin B, cefalotin, polimiksini (koji se koriste za liječenje mikrobnih infekcija), ciklosporin, takrolimus (koji se koristi za smanjenje aktivnosti imunološkog sustava).
amphotericin or co-trimoxazole, to treat fungal and bacterial infections
amfotericin ili kotrimoksazol, za liječenje gljivičnih i bakterijskih infekcija
Ampoule
Ampula
AMPOULE
AMPULE
Ampoule (glass)
Ampula (staklena)
ampoule (glass)
Ampule (stakla)
ampoule (glass)
ampule (staklene)
ampoule (PE)
ampula (PE)
Ampoule carriers are stored in canister, and in liquid nitrogen containers.
Nosači ampula čuvaju se u kanistru, u spremnicima s tekućim dušikom.
Ampoule coloured ring
Prsten u boji na ampuli
Ampoule coloured rings
Ampula/ boje prstenova
Ampoule coloured rings
Prsten u boji na ampuli
AMPOULE LABEL
NALJEPNICA AMPULE
AMPOULE LABEL
NALJEPNICA NA AMPULI
AMPOULE LABEL FOR SOLVENT
NALJEPNICA NA AMPULI OTAPALA
AMPOULE WITH 1 ML
AMPULA S 1 ML
AMPOULE WITH 2 ML
AMPULA S 2 ML
Ampoules are intended for single use only, any unused portions must be discarded.
Ampule su namijenjene samo za jednokratnu primjenu, neupotrebljeni dio lijeka se mora zbrinuti.
Ampoules are packed in pouches, one pouch contains 8 ampoules which correspond with 4 days of treatment.
Ampule su zapakirane u vrećice, s time da jedna vrećica sadrži 8 ampula, što odgovara količini potrebnoj za 4 dana liječenja
Ampoules of 1,000, 2,000 or 4,000 doses
(Ampule od 1.000, 2.000 ili 4.000 doza)
AMPOULES OR VIALS
AMPULE ILI BOČICE
Ampoules with 1 ml nebuliser solution (for the use of Breelib or I-Neb AAD):
Ampule s 1 ml otopine za atomizator (za primjenu pomoću uređaja Breelib ili I-Neb AAD):
Ampoules with 2 ml nebuliser solution (for the use of Venta-Neb):
Ampule s 2 ml otopine za atomizator (za primjenu pomoću uređaja Venta-Neb):
amprenavir and raltegravir (especially in fed conditions)
Inhibitori integraze
amprenavir and raltegravir (especially in fed conditions)
raltegravir (posebice nakon obroka) kod bolesnika može
Amprenavir and ritonavir levels may increase on stopping St John’s wort.
Nakon prestanka uzimanja Gospine trave, razine amprenavira i ritonavira se mogu povećati.
Amprenavir AUC ↓ 0.67 (0.55-0.80)
Amprenavir AUC  0,67 (0,55-0,80)
Amprenavir AUC 
Amprenavir: AUC  30
Amprenavir AUC  0.89 (0.77-
Amprenavir AUC  0,89 (0,77-1,03)
Amprenavir AUC ↑ 69% Amprenavir Cmin  77%
Amprenavir AUC  69% Amprenavir Cmin 77
Amprenavir AUC  0.67 (0.55-0.80)
Amprenavir AUC  0,67 (0,55-0,80)
Amprenavir AUC12: ↓ 0.65
Amprenavir AUC12:  0,65
Amprenavir binds to the active site of HIV-1 protease and thereby prevents the processing of viral gag and gag-pol polyprotein precursors, resulting in the formation of immature non-infectious viral particles.
Amprenavir se vezuje za aktivno mjesto HIV-1 proteaze i time sprječava obradu virusnih gag i gag-pol poliproteinskih prekursora što rezultira stvaranjem nezrelih neinfektivnih virusnih čestica.
Amprenavir C12: ↓ 0.64
Amprenavir C12:  0,64
Amprenavir Cmax ↓ 0.75 (0.63-0.89)
Amprenavir Cmax  0,75 (0,63-0,89)
Amprenavir Cmax ↔ 0.97 (0.85-1.10)
Amprenavir Cmax  0,97 (0,85-1,10)
Amprenavir Cmax 
Amprenavir: Cmax  51
Amprenavir Cmax 
Ezomeprazol
Amprenavir Cmax  0.97 (0.85-1.10)
Amprenavir Cmax  0,97 (0,85-1,10)
Amprenavir Cmax  62%
Amprenavir Cmax 62
Amprenavir Cmax  0.75 (0.63-0.89)
Amprenavir Cmax  0,75 (0,63-0,89)
Amprenavir Cmax: ↓ 0.66
Amprenavir Cmax:  0,66
Amprenavir Cmin (C12h) 
Amprenavir: Cmin (C12h) 
Amprenavir Cmin ↓ 0.65 (0.49-0.85)
Amprenavir Cmin  0,65 (0,49-0,85)
Amprenavir Cmin ↓ 0.81 (0.69-0.96)
Amprenavir Cmin  0,81 (0,69-0,96)
Amprenavir Cmin  77%
Amprenavir Cmin 77
Amprenavir Cmin  0.65 (0.49-0.85)
Amprenavir Cmin  0,65 (0,49-0,85)
Amprenavir Cmin  0.81 (0.69-0.96)
Amprenavir Cmin  0,81 (0,69-0,96)
Amprenavir concentrations are significantly reduced.
Fosamprenavir: Koncentracije amprenavira značajno su smanjene.
Amprenavir metabolism is inhibited by ritonavir, via inhibition of CYP3A4, resulting in increased plasma concentrations of amprenavir.
Ritonavir inhibira metabolizam amprenavira putem inhibicije CYP3A4, što rezultira povećanim koncentracijama amprenavira u plazmi.
Amprenavir 
Maravirok: AUC12  2,49
Amprenavir  expected
Amprenavir očekuje se 
amprenavir.
amprenavirom.
Amprenavir/ritonavir and
Amprenavir/ritonavir i
Amprenavir:
Amprenavir :
Amprenavir: AUC * Amprenavir: Cmin *
Amprenavir: AUC 
Amprenavir: AUC  18%
Amprenavir: Cmax  35
Amprenavir: AUC  30% Amprenavir: Cmin (C12h) 
Amprenavir: AUC  30
Amprenavir: AUC12  0.65
Amprenavir: AUC 
Amprenavir: AUC12  0.65
Amprenavir: AUC12  0,65
Amprenavir: C12  0.64
Amprenavir: C12  0,64
Amprenavir: Cmax 
Dolutegravir
Amprenavir: Cmax  0.66
Amprenavir: Cmax  0,66
Amprenavir: Cmax  35%
Amprenavir: AUC 
Amprenavir: Cmin (C12h) 
Amprenavir: AUC  18
Amprenavir: Cmin 
Cmax  24
Amprenavir: Cmin  42 %*
Amprenavir: AUC  26%* Amprenavir: Cmin  42
Amprenavir:  expected
Amprenavir: Cmax 
Amprenavir:  expected
fenitoina.
AMS has been reported with use of IVIG or SCIG.
S upotrebom intravenskih (i.v.Ig) ili supkutanog imunoglobulina (s.c.Ig) zabilježena je pojava AMS-a.
AMS is characterised by the following signs and symptoms: severe headache, neck stiffness, drowsiness, fever, photophobia, nausea, and vomiting.
AMS obilježavaju slijedeći znakovi i simptomi: jaka glavobolja, ukočenost u vratu, pospanost, vrućica, fotofobija, mučnina i povraćanje.
AMS may occur more frequently in association with high-dose (2 g/kg) IVIg treatment.
Sindrom aseptičkog meningitisa se može češće javiti u vezi s liječenjem visokim dozama (2 g/kg) i.v. imunoglobulina.
Amylase
amilaza
amylase
amilaze
Amylase increased
povišena razina amilaze
Amylase increased
Povišenje amilaze
amylase increased, blood bilirubin increased, hypercalcaemia
povišene vrijednosti amilaze, povišene vrijednosti bilirubina u krvi, hiperkalcijemija
amylolytic activity:
amilolitička aktivnost:
amylolytic activity: not less than 1,600 units* proteolytic activity: not less than 130 units*
amilolitička aktivnost: ne manje od 1600 jedinica* proteolitička aktivnost: ne manje od 130 jedinica
Amylopectin Potato starch Magnesium stearate Lactose
Amilopektin Krumpirski škrob Magnezij stearat Laktoza
Amyvid 1900 MBq/mL solution for injection Amyvid 800 MBq/mL solution for injection Florbetapir (18F)
Amyvid 1900 MBq/ml otopina za injekciju Amyvid 800 MBq/ml otopina za injekciju florbetapir (18F)
Amyvid 1900 MBq/mL solution for injection Florbetapir (18F)
Amyvid 1900 MBq/ml otopina za injekciju florbetapir (18F)
Amyvid 1900 MBq/mL: 1 mL of solution for injection contains 1900 MBq of florbetapir (18F) at the date and time of calibration.
Amyvid 1900 MBq/ml: 1 ml otopine za injekciju sadrži 1900 MBq florbetapira (18F) na dan i sat kalibriranja (ToC).
Amyvid 1900 MBq/mL: One multidose vial of 10 mL capacity containing 1 to 10 mL of solution, corresponding to 1900 to 19000 MBq at date and time of calibration.
Amyvid 1900 MBq/ml: Jedna višedozna bočica od 10 ml koja sadrži 1 do 10 ml otopine, što odgovara 1900 do 19000 MBq na dan i sat kalibriranja.
Amyvid 800 MBq/mL solution for injection Florbetapir (18F)
Amyvid 800 MBq/ml otopina za injekciju florbetapir (18F)
Amyvid 800 MBq/mL: 1 mL of solution for injection contains 800 MBq of florbetapir (18F) at the date and time of calibration.
Amyvid 800 MBq/ml: 1 ml otopine za injekciju sadrži 800 MBq florbetapira (18F) na dan i sat kalibriranja (ToC).
Amyvid images should only be interpreted by readers trained in the interpretation of PET images with florbetapir (18F).
Snimke dobivene uz primjenu lijeka Amyvid smiju interpretirati samo osobe obučene za interpretaciju PET snimaka dobivenih uz primjenu florbetapira (18F).
Amyvid is a clear, colourless solution for injection.
Amyvid je bistra i bezbojna otopina za injekciju.
Amyvid is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of β-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment.
Amyvid je radiofarmak indiciran za oslikavanje pozitronskom emisijskom tomografijom (PET) gustoće β- amiloidnih neuritičkih plakova u mozgu odraslih bolesnika s oštećenjem kognitivne funkcije u kojih se pretraga provodi radi utvrđivanja Alzheimerove bolesti i drugih uzroka oštećenja kognitivne funkcije.
Amyvid is given as an injection into your vein (intravenous injection) followed by a flush of sodium chloride solution to ensure full delivery of the dose.
Amyvid se primjenjuje u obliku injekcije u venu (intravenska injekcija) nakon koje se daje otopina natrijeva klorida kojom se osigurava primjena cjelokupne doze.
Amyvid is given to people with memory problems so that doctors can perform a type of brain scan, called a PET scan.
Amyvid se daje osobama koje imaju tegoba s pamćenjem kako bi liječnici mogli provesti oslikavanje mozga koje se naziva PET oslikavanjem.
Amyvid is not intended for use in children and adolescents.
Amyvid nije namijenjen za primjenu u djece i adolescenata.
Amyvid is supplied in 10 mL or 15 mL clear Type I borosilicate glass vials with FluroTec-coated chlorobutyl elastomeric stoppers and aluminium seals.
Amyvid dolazi u bočici od 10 ml ili 15 ml od prozirnog borosilikatnog stakla tipa I s čepom od klorbutil elastomera obloženog FluroTec-om te aluminijskim zaštitnim zatvaračem.
Amyvid must not be used after the expiry date which is stated on the shield label after EXP.
Amyvid se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na naljepnici na zaštitnom spremniku iza „Rok valjanosti“.
An 18-week study was conducted to evaluate the efficacy and safety of saxagliptin 5 mg in combination with metformin (403 patients), compared with sitagliptin 100 mg in combination with metformin (398 patients) in 801 patients with inadequate glycaemic control on metformin alone.
Ispitivanje u trajanju od 18 tjedana provedeno je zbog procjene djelotvornost i sigurnost primjene saksagliptina od 5 mg u kombinaciji s metforminom (403 bolesnika) u usporedbi sa sitagliptinom od 100 mg u kombinaciji s metforminom (398 bolesnika) u 801 bolesnika s neodgovarajućom kontrolom glikemije koji su se liječili samo metforminom.
An 80 mg dose of telmisartan administered to healthy volunteers almost completely inhibits the angiotensin II evoked blood pressure increase.
Doza od 80 mg telmisartana primjenjena u zdravih pojedinaca gotovo u potpunosti inhibira povišenje krvnog tlaka uzrokovano angiotenzinom II.
an abnormal blood test result for bilirubin, a chemical produced from the normal breakdown of red blood cells
poremećeni nalaz pretrage krvi za bilirubin, kemijske tvari koja se stvara normalnom razgradnjom crvenih krvnih stanica
an abnormal blood test result for creatinine, a chemical excreted in the urine, and a measure of kidney function
poremećeni nalaz pretrage krvi za kreatinin, kemijske tvari koja se izlučuje u mokraći i koja je mjera funkcije bubrega
An abnormal heart trace (QT interval prolongation) potentially leading to an abnormal heart rhythm
Abnormalni nalaz srca (produljenje QT intervala) koji može dovesti do abnormalnog srčanog ritma
An abnormal response by the body’s immune system is thought to play an important part in the process which damages the CNS.
Smatra se da abnormalni odgovor imunološkog sustava organizma ima važnu ulogu u procesu oštećenja središnjeg živčanog sustava.
an abnormal variation of hormones and liver enzyme levels in the blood
poremećene vrijednosti razine hormona i enzima jetre u krvi
an abnormality in your electrocardiogram called atrioventricular block;
promjene na elektrokardiogramu koje se zovu atrioventrikularni blok;
an abnormality of red blood cells (sickle cell anaemia)
poremećaj crvenih krvnih stanica (anemiju srpastih stanica)
an abnormality of the red blood cells (sickle cell anaemia);
poremećaj broja crvenih krvnih stanica (anemija srpastih stanica);
an abnormally high alkalinity of the blood and other body tissues
abnormalno visoka alkalnost krvi i drugih tkiva
An absolute benefit of 13 percentage points in favour of the Herceptin arm was estimated in terms of 3-year event-free survival rate (65 % versus 52 %).
Za skupinu koja je primala Herceptin procijenjena je apsolutna korist od 13 postotnih bodova za stopu trogodišnjeg preživljenja bez štetnih događaja (65 % naspram 52 %).
An accelerated elimination procedure as defined in the teriflunomide Summary of Product Characteristics is recommended or alternatively washout period should not be shorter than 3.5 months.
Preporučuje se ubrzani postupak eliminacije opisan u Sažetku opisa svojstava lijeka za teriflunomid ili, u drugom slučaju, razdoblje ispiranja lijeka iz organizma ne smije biti kraće od 3,5 mjeseca.
An accelerated elimination procedure can be used at any time after discontinuation of teriflunomide (see section 4.6 and 5.2 for procedural details).
Postupak ubrzane eliminacije može se primijeniti u bilo kojem trenutku nakon prekida primjene teriflunomida (za pojedinosti o postupku vidjeti dijelove 4.6 i 5.2).
An accompanying improvement in the glomerular filtration rate (GFR) was not observed during the first three months of treatment.
Pridruž eno poboljš anje brzine glomerularne filtracije nije zabiljež eno tijekom prva tri mjeseca liječ enja.
An accurate and validated assay for either ALK or ROS1 is necessary for the selection of patients for treatment with XALKORI (see section 5.1 for information on assays used in the trials).
Pri odabiru bolesnika za liječenje lijekom XALKORI neophodno je provesti testiranje za ALK ili ROS1 pomoću točnog i validiranog testa (vidjeti dio 5.1 za podatke o testovima koji su korišteni u ispitivanjima).
An active infection at the operative site
aktivnom infekcijom na mjestu kirurškog zahvata
An acute ocular infection may be masked by the topical use of anti-inflammatory medicinal products.
Akutna infekcija oka može biti prikrivena topikalnom primjenom protuupalnih lijekova.
An acute ocular infection may be masked by the topical use of anti-inflammatory medicinal products.
Akutne očne infekcije mogu biti prikrivene zbog topikalne primjene protuupalnih lijekova.
An ad hoc efficacy analysis was performed after all patients who had received lumacaftor/ivacaftor (lumacaftor 400 mg/ivacaftor 250 mg q12h) in Trial 1 or Trial 2 had completed the Week 24 Visit in Trial 3 (up to 48 weeks of treatment).
Ad hoc analiza djelotvornosti provedena je nakon što su svi bolesnici koji su primali lumakaftor/ivakaftor (lumakaftor 400 mg/ivakaftor 250 mg svakih 12 sati) u ispitivanju 1 ili ispitivanju 2 završili dolazak u 24. tjednu u ispitivanju 3 (do 48 tjedana liječenja).
An add-on placebo-controlled study of 24-week duration was conducted to evaluate the efficacy and safety of saxagliptin in combination with glibenclamide in patients with inadequate glycaemic control at enrollment (HbA1c 7.5-10%) on a sub-maximal dose of glibenclamide alone.
Placebom kontrolirano ispitivanje saksagliptina u trajanju od 24 tjedna provedeno je zbog procjene djelotvornosti i sigurnosti saksagliptina u kombinaciji s glibenklamidom u bolesnika s neodgovarajućom kontrolom glikemije (HbA1c 7,5%–10%) pri uključenju u ispitivanje uz uzimanje submaksimalne doze samo glibenklamida.
An add-on to metformin placebo-controlled study of 12-week duration was conducted to evaluate the efficacy and safety of saxagliptin 2.5 mg twice daily in combination with metformin in patients with inadequate glycaemic control (HbA1c 7-10%) on metformin alone.
Provedeno je placebom kontrolirano ispitivanje saksagliptina kao dodatka metforminu u trajanju od 12 tjedana zbog procjene djelotvornosti i sigurnosti saksagliptina primijenjenog u dozi od 2,5 mg dvaput na dan u kombinaciji s metforminom u bolesnika s neodgovarajućom kontrolom glikemije (HbA1c 7-10%) liječenih samo metforminom.
An additional 4% (n=27) of patients from the two studies had incomplete MTTs and were not randomised.
Testovi tolerancije na manitol (MTT) za dodatnih 4% (n = 27) pacijenata iz dvaju ispitivanja nisu bili potpuni te ti pacijenti također nisu bili razvrstani.
An additional air buffer of at least 3 ml is included in the 50 ml syringe.
Dodatni jastučić zraka od najmanje 3 ml uključen je u štrcaljku od 50 ml .
An additional analysis of efficacy data by KRAS status did not identify a subset of patients who benefited from Vectibix in combination with oxaliplatin- or irinotecan-based chemotherapy and bevacizumab.
Dodatna analiza podataka o djelotvornosti prema statusu KRAS gena nije identificirala podskupinu bolesnika koji bi imali korist od lijeka Vectibix u kombinaciji s kemoterapijom na bazi oksaliplatina ili irinotekana i bevacizumaba.
An additional contraceptive method is recommended in case of severe diarrhoea (see section 4.4).
U slučaju teškog proljeva preporučuje se dodatna metoda kontracepcije (vidjeti dio 4.4)
An additional contraceptive method is recommended in case of severe diarrhoea (see section 4.4).
U slučaju teškog proljeva preporučuje se korištenje dodatne kontracepcijske metode (vidjeti odjeljak 4.4).
An additional four HES patients were found to be FIP1L1- PDGFRα-positive in other 3published reports.
Dodatna četiri HES bolesnika su otkrivena kao FIP1L1-PDGFRα-pozitivni u druga 3 objavljenja slučaja.
An additional four HES patients were found to be FIP1L1-PDGFRα-positive in other 3 published reports.
Dodatna 4 HES bolesnika su otkrivena kao FIP1L1-PDGFRα-pozitivni u druga 3 objavljenja slučaja.
An additional four HES patients were found to be FIP1L1-PDGFRα-positive in other 3 published reports.
Dodatna četiri bolesnika s HES-om bila su pozitivna za FIP1L1-PDGFRα u ostala 3 objavljenja slučaja.
An additional infusion, given at least one year after the first one, can be considered if the patient’s disease comes back.
Ako dođe do relapsa bolesti u bolesnika, može se razmotriti primjena dodatne infuzije, koja se primjenjuje barem godinu dana nakon prve infuzije.
An additional one to two Suboxone 2 mg/0.5 mg may be administered on day one depending on the individual patient’s requirement.
Dodatne jedna ili dvije tablete lijeka Suboxone 2 mg/0,5 mg mogu se primijeniti prvog dana ovisno o potrebama pojedinog bolesnika.
An additional one to two tablets of the Suboxone 2 mg/0.5 mg may be administered on day 1 depending on your needs.
Dodatno se može uzeti jedna ili dvije tablete lijeka Suboxone od 2 mg/0,5 mg prvog dana, ovisno o Vašim potrebama.
An additional one to two tablets of the Suboxone 2 mg/0.5 mg may be administered on day 1 depending on your needs.
Dodatno se može uzeti jedna ili dvije tablete lijeka Suboxonea od 2 mg/0,5 mg prvog dana, ovisno o Vašim potrebama.
An additional overfill is included in each vial to ensure that 250 µg of romiplostim can be delivered (see vial content table below).
Svaka bočica sadrži dodatni suvišak kako bi se osigurala doza od 250 µg romiplostima (vidjeti tablicu sadržaja bočice u nastavku).
An additional overfill is included in each vial to ensure that 250 µg of romiplostim can be delivered.
Svaka bočica sadrži dodatni suvišak kako bi se osigurala doza od 250 µg romiplostima.
An additional overfill is included in each vial to ensure that 50 micrograms of tilmanocept can be delivered.
Svaka bočica sadrži dodatni suvišak kako bi se osigurala doza od 50 mikrograma tilmanocepta.
An additional overfill is included in each vial to ensure that 500 µg of romiplostim can be delivered (see vial content table below).
Svaka bočica sadrži dodatni suvišak kako bi se osigurala doza od 500 µg romiplostima (vidjeti tablicu sadržaja bočice u nastavku).
An additional overfill is included in each vial to ensure that 500 µg of romiplostim can be delivered.
Svaka bočica sadrži dodatni suvišak kako bi se osigurala doza od 500 µg romiplostima.
An additional retrospective analysis showed a nominally significant reduction in the incidence rates of stent thrombosis compared with placebo (see Table 3).
Dodatna je retrospektivna analiza pokazala nominalno značajno smanjenje stope incidencije tromboze stenta u usporedbi s placebom (vidjeti tablicu 3).
An additional study compared Cimzia given alone with placebo in 218 patients whose response to other medicines such as methotrexate had been inadequate.
Dodatno ispitivanje usporedilo je primjenu samog lijeka Cimzia s placebom u 218 bolesnika koji su imali neprimjeren odgovor na druge lijekove poput metotreksata.
An additional study in 945 previously untreated advanced melanoma patients investigated Opdivo in combination with ipilimumab, Opdivo used alone or ipilimumab used alone.
U dodatnom se ispitivanju, u 945 bolesnika s uznapredovalim melanomom koji nisu prethodno bili liječeni, proučavao lijek Opdivo u kombinaciji s ipilimumabom, kao monoterapija ili ipilimumab kao monoterapija.
An additional study in adults with schizophrenia looked at the long-term effects of Invega in preventing new symptoms for up to 35 weeks in 207 patients who had initially been treated over a 14-week period, and another study involving 228 adolescents looked at the longer-term effects of treatment with Invega over 8 and 26 weeks compared with aripiprazole (another antipsychotic medicine).
Dodatno ispitivanje provedeno u odraslih osoba oboljelih od shizofrenije istražilo je dugoročno djelovanje lijeka Invega u sprječavanju novih simptoma tijekom 35 tjedana u 207 bolesnika koji su početno liječeni tijekom razdoblja od 14 tjedana, a drugo je ispitivanje obuhvatilo 228 adolescenata i istražilo je dugoročno djelovanje liječenja lijekom Invega tijekom 8 i 26 tjedana u usporedbi s aripiprazolom (drugim antipsihotikom).
An additional study looked at the effectiveness of Exjade in 184 patients who could not be treated with deferoxamine, including patients with beta thalassaemia major and with other types of anaemia.
Provedeno je i dodatno ispitivanje u okviru kojega je razmatrana djelotvornost lijeka Exjade, i to na 184 bolesnika koji se nisu mogli liječiti deferoksaminom, uključujući bolesnike s beta-talasemijom major i drugim vrstama anemije.
An additional study measured the ‘acceptability’ of PecFent, by the patients rating how satisfied they were with PecFent, and how easy and convenient they found it to use.
Dodatno ispitivanje izmjerilo je „prihvatljivost” lijeka PecFent tako što su bolesnici ocjenjivali svoje zadovoljstvo lijekom PecFent, te jednostavnost i praktičnost uporabe.